Singapore - Amneal Biosciences (a US based pharmaceutical manufacturing company) received approval for its Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/mL dosage strength.  Poised to launch, the product will be sold in 1 mL single-dose vials as well as in 5 mL and 10 mL multiple dose vials.  With just the Kenalog-40 brand currently on the market, Amneal's triamcinolone acetonide will be the only AP-rated generic equivalent injectable suspension available.

"We are very pleased to launch the only generic injectable of triamcinolone, bringing this affordable medication to patients and healthcare providers," says Amneal Biosciences President Charles Lucarelli. "We will continue to focus on expanding our portfolio to provide quality generic injectables to our healthcare system."

Annual U.S. sales of Kenalog-40 injection were $146 million according to October 2017 IQVIA market data.  Triamcinolone acetonide injectable suspension will be available direct and through wholesalers and distributors.